Merck & Co. Inc., known as MSD outside of the United States and Canada, has announced that Health Canada has approved KEYTRUDA® (pembrolizumab) for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer in combination with chemoradiotherapy $(CRT)$. This approval is based on the positive results from the Phase 3 KEYNOTE-A18/ENGOT-cx11/GOG-3047 trial, which demonstrated significant improvements in progression-free survival and overall survival for patients receiving the treatment compared to those receiving a placebo. This marks the first approval in Canada for KEYTRUDA® in combination with CRT, providing a vital new therapeutic option for patients battling this stage of cervical cancer.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。